Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review
Journal Title
Frontiers in Oncology
Publication Type
Review
Abstract
Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. Immunotherapy with immune checkpoint inhibitors (ICI) has significantly improved outcomes in some patients, however 80-85% of patients receiving immunotherapy develop primary resistance, manifesting as a lack of response to therapy. Of those that do have an initial response, disease progression may occur due to acquired resistance. The make-up of the tumour microenvironment (TME) and the interaction between tumour infiltrating immune cells and cancer cells can have a large impact on the response to immunotherapy. Robust assessment of the TME with accurate and reproducible methods is vital to understanding mechanisms of immunotherapy resistance. In this paper we will review the evidence of several methodologies to assess the TME, including multiplex immunohistochemistry, imaging mass cytometry, flow cytometry, mass cytometry and RNA sequencing.
Publisher
Frontiers
Keywords
RNAseq analysis; cytometry; immune interaction; immunohistochemistry; immunotherapy; non-smal cell lung cancer; tumour microenvironment
Department(s)
Medical Oncology
PubMed ID
37143952
Open Access at Publisher's Site
https://doi.org/10.3389/fonc.2023.1129195
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-03 07:58:31
Last Modified: 2023-08-03 08:01:33

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙